Publications
PUBLICATION HIGHLIGHTS
Editor: Zagaria MA, ed. Polypharmacy. Clin Geriatr Med. 2017. May; 33(2). 153-292. ISBN Number 9780323528405 E-ISBN 9780323528412 https://www.amazon.com/Polypharmacy-Issue-Clinics-Geriatric-Medicine/dp/0323528406
Preface: Zagaria MA. Inroads into Polypharmacy: Moving Forward with Tools, Deprescribing, and Philosophical Reflection. Clin Geriatr Med. 2017 May;33(2):ix-x. doi: 10.1016/j.cger.2017.02.001. Epub 2017 Feb 23. PMID: 28364997 https://www.amazon.com/Polypharmacy-Issue-Clinics-Geriatric-Medicine/dp/0323528406
Editorial (Invited): Zagaria MA. Innovation: The promise of financial viability for pharmacy practice opportunities. Journal of Pharmacy Practice and Research (JPPR), official journal of the Society of Hospital Pharmacists of Australia (SHPA). 2015;45(3):259-260.
Author: Articles, invited editorials, book chapters, preface, and introductions; inaugurated both the Issues in Pharmacotherapy column in the American Journal for Nurse Practitioners and the monthly Senior Care pharmacy column in the national, peer-reviewed journal U.S. Pharmacist; continues pharmacy column quarterly, to date.
PUBLICATIONS
1. Zagaria MA. Small-Intestine Cancer, IBD, and the Role of Gut Dysbiosis. US Pharm. 2018;43(12): 8-10
2. Zagaria MA. Nuances of diabetic foot osteomyelitis in older adults. US Pharm. 2018;43(10):10-12.
3. Zagaria MA. Treatment nuances for Kaposi sarcoma in older adults. US Pharm. 2018;43(8): 8-11.
4. Zagaria MA. Nonopioid analgesia following soft-tissue–tumor surgery. US Pharm. 2018;43(6): 6,8-10.
5. Zagaria MA. Risk of Osteomyelitis with Joint Replacement. US Pharm. 2018;43(4):16-18.
6. Zagaria MA. Cardiovascular Considerations With Prescription Opioids for Chronic Pain. US Pharm. 2018;43(2):6-9.
7. Zagaria MA. Chronic Pancreatitis Pain: Opioid and Vitamin D Considerations. US Pharm. 2017:42(12):6-8.
8. Zagaria MA. U.S. Medical Product Integrity: Protecting Older Adults. US Pharm. 2017;42(10):8-10.
9. Zagaria MA. Nocturia in Older Adults: Highlighting Nocturnal Polyuria. US Pharm. 2017;42(8):Epub
10. Zagaria MA. Medication Therapy Management: Status Overview, Innovation, and Practice Resources. US Pharm. 2017;42(6):7-9.
11. Zagaria MA, ed. Polypharmacy. Clin Geriatr Med. 2017. May; 33(2). 153-292. ISBN Number 9780323528405 E-ISBN 9780323528412 https://www.amazon.com/Polypharmacy-Issue-Clinics-Geriatric-Medicine/dp/0323528406
12. Zagaria MA. Inroads into Polypharmacy: Moving Forward with Tools, Deprescribing, and Philosophical Reflection. Clin Geriatr Med. 2017 May;33(2):ix-x. doi: 10.1016/j.cger.2017.02.001. Epub 2017 Feb 23. PMID: 28364997 https://www.amazon.com/Polypharmacy-Issue-Clinics-Geriatric-Medicine/dp/0323528406
13. Zagaria MA. Migraine Headache: Connection to TIA and Ischemic Stroke? US Pharm. 2017;42(4)4-7.
14. Zagaria MA. Myocardial Infarction in Women: Milder Symptoms, Aspirin, and Angioplasty. US Pharm. 2017;42(2):5-7.
15. Zagaria MA. Late-onset myasthenia gravis: Fatigability and fluctuating weakness. US Pharm. 2017;42(1)4-6.
16. Zagaria MA. Symptomatic bradycardia: Ophthalmic beta-blockers in older adults. US Pharm. 2016;41(10):15-17.
17. Zagaria MA. Ovarian cancer: Treatment considerations in older women. US Pharm. 2016;41(9):18-20.
18. Zagaria MA. OTC analgesic use in older adults: Keeping kidneys healthy. US Pharm. 2016;41(8):7-9.
19. Zagaria MA. Systemic corticosteroid-associated psychiatric adverse effects. US Pharm. 2016;41(7):16-18.
20. Zagaria MA. Polymyalgia rheumatica: Sudden pain and stiffness in seniors. US Pharm. 2016;41(6):27-29.
21. Zagaria MA. Male Preconception Health: Impact of Age, Medications, and Other ExposuresUSPharm. 2016;41(5):15-17.
22. Zagaria MA. Postoperative Endophthalmitis After Cataract Surgery. US Pharm. 2016;41(4):8,10-11.
23. Zagaria MA. Central Poststroke Pain Syndrome. US Pharm. 2016;41(3):21-23.
24. Zagaria MA. Periodontitis Risk for AtheroscleroticVascular Disease? US Pharm. 2016;41(2):9-11.
25. Zagaria MA. Hearing Impairment Age- and Drug-Related Causes.US Pharm. 2016;41(1):19-21.
26. Zagaria MA. Healthy Aging Raising Nutritional Awareness for Seniors. US Pharm. 2015;40(12):13-15.
27. Zagaria MA. Recognizing Antipsychotic-Induced Movement Disorders. US Pharm. 2015;40(11):22-25.
28. Zagaria MA. Brexpiprazole: A newly approved atypical antipsychotic agent. US Pharm. 2015;40(10):13-15.
29. Zagaria MA. (Invited Editorial). Innovation: The promise of financial viability for pharmacy practice opportunities. Journal of Pharmacy Practice and Research, official journal of the Society of Hospital Pharmacists of Australia (SHPA). 2015;45(3):259-260.
30. Zagaria MA. Intimate partner violence: Empathy and a patient-centered approach. US Pharm. 2015;40(9):20-23.
31. Zagaria MA. Genitourinary syndrome of menopause: Vaginal estrogen for urinary symptoms. US Pharm. 2015;40(8):8,10,11.
32. Zagaria MA. Central sleep apnea: Impact of opioids, benzodiazepines, and CYP3A4 inhibitors. US Pharm. 2015;40(7):21-24.
33. Zagaria MA. Heel and Back-of-the-foot pain in older adults. US Pharm. 2015;40(6):9-11.
34. Zagaria MA. Age-related sarcopenia. US Pharm. 2015;40(5):16-18.
35. Zagaria MA. HSV Keratitis: An Important Infectious Cause of Blindness. US Pharm. 2015;40(4):16-18.
36. Zagaria MA. Periodic Limb Movement Disorder, Restless Legs Syndrome, and Pain. US Pharm. 2015;40(3):19-21.
37. Zagaria MA. Subclinical hypothyroidism: Risk of Cardiovascular Events. US Pharm. 2015;40(2):27-30.
38. Zagaria MA. Questionable medication benefit in advanced dementia: Decision-making tools. US Pharm. 2015;40(1):21-23.
39. Zagaria MA. Fecal transplantation for recurrent Clostridium difficile infection. US Pharm. 2014;39(12):20-22.
40. Zagaria MA. Borderline personality disorder in late life: A medication adherence variable. US Pharm. 2014;39(11):25-28.
41. Zagaria MA. Academic detailing: Accurate, relevant, balanced, and engaging. US Pharm. 2014;39(10):16-19.
42. Zagaria MA. Risks for endometrial cancer: Obesity, hypertension, and diabetes. US Pharm. 2014;39(9):30,32-33.
43. Zagaria MA. Urinary incontinence: Urologic and medication etiology in seniors. US Pharm. 2014;39(8):20-23.
44. Zagaria MA. Recognizing causes of dyspnea to prevent hospital admissions. US Pharm. 2014;39(7):16-18.
45. Zagaria MA. Metatarsophalangeal Osteoarthritis: Pain in the Big Toe Joint. US Pharm. 2014;39(6):31-33.
46. Zagaria MA. Geriatric emergency department care: The pharmacist’s role. US Pharm. 2014;39(5):18-21.
47. Zagaria MA. Hepatitis C Alert: Baby Boomers Should Be Tested. US Pharm. 2014;39(4):18-20.
48. Zagaria MA. Metrics to Define and Measure Quality Pain Management. US Pharm. 2014;39(3):18-21.
49. Zagaria MA. Mechanical Heart Valves: Contraindication for Dabigatran Therapy. US Pharm. 2014;39(2)32-34. .
50. Zagaria MA. Head Injury and Chronic Traumatic Encephalopathy. US Pharm. 2014:39(1):20-23.
51. Zagaria MA. Inflammatory bowel disease: Nuances of drug therapy in seniors and the role of vitamin D. US Pharm. 2013;38(12):18-20.
52. Zagaria MA. Bleeding risk with SSRIs: Surgery and seniors. US Pharm. 2013;38(11):20-22.
53. Zagaria MA. Rasagiline update: Postmarket evidence and clinical considerations. US Pharm. 2013;38(10):18-20.
54. Zagaria MA. Access to health care: Influential factors and cultural competence. US Pharm. 2013;38(9):20-22.
55. Zagaria MA. Nephrotic syndrome: Medication and other related risks. US Pharm. 2013;38(8):18-20.
56. Zagaria MAE. Diffuse interstitial lung disease. US Pharm. 2013;38(7):37-39.
57. Zagaria MA. Common benign skin growths in older adults. US Pharm. 2013;38(6):37-39.
58. Zagaria MA. When communications become difficult: Is it dementia? US Pharm. 2013;38(5):30-32.
59. Zagaria MA. Antibiotic therapy: Adverse effects and dosing considerations. US Pharm. 2013:38(4):18-20.
60. Zagaria MA. Cervical spondylosis: Neck pain, stiffness, ad associated features. US Pharm. 2013;38(3):17-19.
61. Zagaria MA. Age-associated vulnerability and cardiovascular function: Medication Therapy Management (MTM). US Pharm. 2013;38(2):24-26.
62. Zagaria MA. Community-based medication management in the U.S. and Australia. US Pharm. 2013;38(1):16-18.
63. Zagaria MA. Management of elevated INR secondary to warfarin use: Challenges,recommendations, and resources. Amer J for Nurse Practitioners. 2012;16(11/12):14-16.
64. Zagaria MA. Laryngopharyngeal reflux (Silent Reflux). US Pharm. 2012;37(12):18-20.
65. Zagaria MA. Vascular dementia: Potentially preventable cognitive impairment. US Pharm. 2012;37(11):22-24.
66. Zagaria MA. Focus on the foot: Changes with age and disease. US Pharm. 2012;37(10):20-24.
67. Zagaria MA. Potentially Inappropriate Medications in Seniors. Amer J for Nurse Practitioners. 2012;16(9/10):26-28.
68. Zagaria MA. Alcohol abuse and dependence in senior women: Risks and recommendations. US Pharm. 2012;37(9):22-25.
69. Zagaria MA. Raising awareness of infectious arthritis. US Pharm. 2012;37(8):23-25.
70. Zagaria MA. Advance directives for medical decisions. US Pharm. 2012;37(7):20-22.
71. Zagaria MA. Medications that worsen and strategies that improve urinary incontinence. US Pharm. 2012;37(6):22-25.
72. Zagaria MA. Pain as a barrier to exercise for successful aging. US Pharm. 2012;37(5):28-30.
73. Zagaria MA. Actinic keratosis: Treating a potential malignancy. US Pharm. 2012;37(4):23-26.
74. Zagaria MA. Long-distance caregiving: Challenges and tips for success. Amer J for Nurse Practitioners. 216(3/4):15-18.
75. Zagaria MA. Syncope: Medications as cause and contributing factors. US Pharm. 2012;37(3):22,26-28.
76. Zagaria MA. Atrial septal defect. US Pharm. 2012;37(2):29-31.
77. Zagaria MA. Preemptive treatment of constipation when opioids are initiated. US Pharm. 2012;37(1):21-24.
78. Zagaria MA. Acute pancreatitis: Risks, causes, and mortality in older adults. US Pharm. 2011;36(12): 24-27.
79. Zagaria MA. Treatment decisions in cardiovascular disease: Focus on beta-blockers in seniors. Amer J for Nurse Practitioners. 2011;15(11/12):23-26.
80. Zagaria MA. Intellectual disability: Highlighting senior care issues. US Pharm. 2011;36(11):29-34.
81. Zagaria MA. Osteoarthritis of the hand: Focus on individualized multimodal therapy. US Pharm. 2011;36(10):22-26.
82. Zagaria MA. Assessing and monitoring medication therapy in seniors. Amer J for Nurse Practitioners. 2011;15(9/10):48-52.
83. Zagaria MA. Urogenital symptoms of menopause: Atrophic vaginitis and atrophic urethritis. US Pharm. 2011;36(9): 22-26.
84. Zagaria MA. Predisposition to infection in the elderly. US Pharm. 2011;36(8): 28-32.
85. Zagaria MA. Proton pump inhibitors: Review of benefits and fracture risk. Amer J for Nurse Practitioners. 2011;15(7/8):47-51.
86. Zagaria MA. Differential diagnosis of asthma and COPD in older adults: Role of spirometry. US Pharm. 2011;36(7): 20-24.
87. Zagaria MA. Drug- and age-related changes in sodium and water regulation. US Pharm. 2011;36(6): 30-33.
88. Zagaria MA. Postherpetic neuralgia: Seniors at Risk. US Pharm. 2011;36(5): 24-26.
89. Zagaria MA. Herpes zoster: Treatment modalities and prevention with zoster vaccine. Amer J for Nurse Practitioners. 2011;15(5/6): 46-52.
90. Zagaria MA. Graves’ Ophthalmopathy. US Pharm. 2011;36(4):20-29.
91. Zagaria MA. Lumbar spinal stenosis. US Pharm. 2011;36(3):ahead of print.
92. Zagaria MA. Antipsychotic-associated metabolic and cardiovascular risks: Monitoring and risk-reduction strategies. Amer J for Nurse Practitioners. 2011;15(3/4):ahead of print.
93. Zagaria MA. Aortic stenosis: Evidence supports surgery. US Pharm. 2011;36(2):20-25.
94. Zagaria MA. Collaborative patient care for seniors with pain. US Pharm. 2011;36(1):21-25.
95. Zagaria MA. Topical corticosteroids: Focus on appropriate potency and vehicle. Amer J for Nurse Practitioners. 2010;14(11/12):36-40.
96. Zagaria MA. Gallstones: Aging and medications increase risk. US Pharm. 2010;35(12):21-24.
97. Zagaria MA. Common adverse effects of antipsychotic agents in the elderly. US Pharm. 2010;35(11):22-26.
98. Zagaria MA. Preventing pneumonia in seniors. US Pharm. 2010;35(10):22-25.
99. Zagaria MA. Sarcopenia: Loss of muscle mass in older adults. US Pharm. 2010;35(9):24-30.
100. Zagaria MA. Vitamin deficiencies in seniors. US Pharm. 2010;35(8):20-27.
101. Zagaria MA. Post-Stroke aspiration pneumonia. US Pharm. 2010;35(7):20-24.
102. Zagaria MA. Subclinical hypothyroidism. US Pharm. 2010;35(6):20-22.
103. Zagaria MA. Chronic opioid therapy for noncancer pain. US Pharm. 2010;35(5):20-24.
104. Zagaria MA. Medications and conditions that potentiate heatstroke: Focus on seniors. Amer J for Nurse Practitioners. 2010;14(5):35-40.
105. Zagaria MA. Kaposi’s Sarcoma: Prognosis varies with form. US Pharm. 2010;35(4):20-23.
106. Zagaria MA. Hot flashes and night sweats. US Pharm. 2010;35(3): 20-24.
107. Zagaria MA. Inhalant agents for asthma, bronchospasm, and COPD: Focus on delivery devices and inhalation technique. Amer J for Nurse Practitioners. 2010;14(3):21-25.
108. Zagaria MA. Warfarin in seniors: Reducing Likelihood of harm. US Pharm. 2010;35(2): 2-22.
109. Zagaria MA. Common causes of drug-induced seizures. US Pharm. 2010;35(1): 20-23.
110. Zagaria MA. Colorectal cancer screening. US Pharm. 2009;34(12): 29-31.
111. Zagaria MA. Progressive supranuclear palsy. US Pharm. 2009;34(11): 20-22.
112. Zagaria MA. The dying patient: Choices, control, and communication – End-of-Life Care. US Pharm. 2009;34(10): 32-34.
113. Zagaria MA. Dyslipidemia: Benefits and risks of statins in primary prevention. Amer J for Nurse Practitioners. 2009;13(10):16-22.
114. Zagaria MA. Obesity: Reality and relevance to health. US Pharm. 2009;34(9): 20-24.
115. Zagaria MA. Amyloidosis: Interference with organ structure and function. US Pharm. 2009;34(8): 21-24.
116. Zagaria MA. Renal dosing: Understanding glomerular filtration rate and estimating creatinine clearance. Amer J for Nurse Practitioners. 2009;13(7/8)32-35.
117. Zagaria MA. Raising awareness about pulmonary embolism: Risk and misdiagnosis. US Pharm. 2009;34(7): 24-26.
118. Zagaria MA. Caring for the aging: Key health care legislation. US Pharm. 2009;34(6): 22-24.
119. Zagaria MA. Assessing pain in the cognitively impaired. US Pharm. 2009;34(5):21-25.
120. Zagaria MA. High-alert medications: Resources for NPs. Amer J for Nurse Practitioners. 2009;13(5):21-28.
121. Zagaria MA. Dermatologic signs of rheumatoid arthritis: Joint and systemic symptoms. US Pharm. 2009;34(4): 22-24.
122. Zagaria MA. Vitamin d deficiency and bone pain: Osteomalacia. US Pharm. 20009;34(3): 22-24.
123. Zagaria MA. Medication-related problems in seniors: Risk factors and tips for appropriate prescribing. Amer J for Nurse Practitioners. 2009;13(3):23-27.
124. Zagaria MA. Venous Thrombosis. US Pharm. 2009;34(2): 22-24.
125. Zagaria MA. Wrist and thumb pain in seniors: Focus on De Quervain’s tenosynovitis. US Pharm. 2009;34(1): 20-22
126. Zagaria MA. Antipsychotics in seniors: Warnings to prevent misuse. US Pharm. 2008;33(11):20-22.
127. Zagaria MA. ACE inhibitors in hypertension: Dosing, comparisons, and compelling indications. Amer J for Nurse Practitioners. 2008;12(11):26-32.
128. Zagaria MA. Nebivolol: New beta-blocker for hypertension. US Pharm. 2008;33(10):20-26.
129. Zagaria MA. Health literacy: Striving for effective communication. Amer J for Nurse Practitioners. 2008;12(9):23-26.
130. Zagaria MA. Postmenopausal vaginal bleeding. US Pharm. 2008;33(9):28-32.
131. Zagaria MA. Sexual activity and STDs among seniors. US Pharm. 2008;33(8):28-30.
132. Zagaria MA. Tuberculosis: A preventable cause of death in the elderly. US Pharm. 2008;33(7):23-25.
133. Zagaria MA. Unintentional acetaminophen overdose: Focus on prevention. Amer J for Nurse Practitioners. 2008;12(6):47-51.
134. Zagaria MA. Baby boomers on brink of healthcare crisis. US Pharm. 2008;33(6): 20-26.
135. Zagaria MA. Consequences of persistent pain. US Pharm. 2008;33(5):28-30.
136. Zagaria MA. Relapsing-remitting multiple sclerosis: Primary and symptomatic management. Amer J for Nurse Practitioners. 2008;12(4):22-26.
137. Zagaria MA. Cutaneous adverse reactions: Stevens-Johnson syndrome. US Pharm. 2008;33(4):20-26.
138. Zagaria MA. Diverticulitis: Overview and management. US Pharm. 2008;33(3):22-25.
139. Zagaria MA. Adverse drug effects: Focus on SSRIs. Amer J for Nurse Practitioners. 2008;12(3):34-38.
140. Zagaria MA. Warfarin and adverse effects US Pharm. 2008;33(2):22-25.
141. Zagaria MA. Causes of seizures in the elderly. US Pharm. 2008;33(1):27-31.
142. Zagaria MA. Pediatric GER & GERD: Overview and management. Amer J for Nurse Practitioners. 2008;12(1):36-42.
143. Zagaria MA. GERD update: The refractory patient. US Pharm. 2007;32(12):20-23.
144. Zagaria MA. Serotonin syndrome US Pharm. 2007;32(11):20-23.
145. Zagaria MA. Seniors and drug development: Encouraging better communication. US Pharm. 2007;32(10):20-25 .
146. Zagaria MA. Atypical antipsychotic agents: Monitoring for metabolic syndrome. Amer J for Nurse Practitioners. 2007;11(10):20-26.
147. Zagaria MA. Screening for dementia in older females. US Pharm. 2007;32(9):20-25.
148. Zagaria MA. Anticholinergic adverse effects. Amer J for Nurse Practitioners. 2007;11(9):20-25.
149. Zagaria MA. Depression: Suicide’s primary remediable risk factor. US Pharm. 2007;32(8):22-27. .
150. Zagaria MA. Pneumoccal Vaccine: Protecting Seniors from Pneumonia. US Pharm. 2007;32(7):22-29.
151. Zagaria MA. Seniors at Risk for Delirium. US Pharm. 2007;32(6):20-24.
152. Zagaria MA. A Healthy Tan? Think Again. US Pharm Student Edition. Summer 2007.
153. Zagaria MA. Geriatric Palliative Care: When the Focus Shifts From Care to Comfort. US Pharm. 2007;32(5):28-34.
154. Zagaria MA. Chronic and Acute Effects of Sun Exposure on the Skin. US Pharm. 2007;32(4):20-26.
155. Zagaria MA. Generic Medications: Issues in Senior Care Pharmacy. US Pharm Generic Drug Review. June 2007:14-15.
156. Zagaria MA. Rate Control in Atrial Fibrillation. US Pharm. 2007;32(2):32-38.
157. Zagaria MA. Vision, Cognition, and Mobility Challenges for Elderly Drivers. US Pharm. 2007;32(1):36-40.
158. Zagaria MA. Family Caregiving: Seniors Continue to Receive and Deliver Care. US Pharm. 2006;31(12):23-29.
159. Zagaria MA. Low Health Literacy: A Safety Concern Among the Elderly. US Pharm. 2006;31(10):28-34.
160. Zagaria MA. Polypharmacy and Potentially Inappropriate Medication Use in the Elderly: Across the Practice-Setting Spectrum. US Pharm. 2006;31(10):112-116.
161. Zagaria MA. Persistent Urinary Incontinence in Older Women: Treatment Can Improve Quality of Life. US Pharm. 2006;31(9):20-34.
162. Zagaria MA. Depression in Older Male Patients. US Pharm. 2006;31(8):34-40.
163. Zagaria MA. Management of COPD in Seniors. US Pharm. 2006;31(7):28-34.
164. Zagaria MA. Heat-Related Illnesses in Older Adults: Identifying Potentially Lethal Conditions. US Pharm. 2006;31(6):34-38.
165. Zagaria MA. Pain Assessment in Older Adults: The Cornerstone of Controlling Pain. US Pharm. 2006;31(5):30-36
166. Zagaria MA. Xerosis: Treating Clinically Dry Skin. US Pharm. 2006;31(4):28-32.
167. Zagaria MA. Parkinson’s Disease: Key Points for the Pharmacist. US Pharm. 2006;31(3):20-30.
168. Zagaria MA. Special considerations for lowering lipids in seniors. US Pharm. 2006;31(2):20-27.
169. Zagaria MA. Osteoarthritis in Seniors. US Pharm. 2006;31(1):20-24.
170. Zagaria MA. Sleep Disorders in Senior Women: Diagnosing and Treating a Common Complaint. Women’s Health in Psychiatry. 2006;2(1):14-23.
171. Zagaria MA. Traumatic Brain Injury in the Elderly. US Pharm. 2005;30(12):20-26.
172. Zagaria MA. Age-Related Macular Degeneration in the Elderly. US Pharm. 2005;30(11):30-36.
173. Zagaria MA. Suppressing Gastric Acid in Seniors with GERD. US Pharm. 2005;30(10):34-39.
174. Zagaria MA. Sleep Disturbances in Older Women: Diagnosing and Treating a Common Complaint. Women’s Health in Primary Care. September 2005;8(8):379-386.
175. Zagaria MA, Buonanno AP. A Patient-Oriented Approach to the Management of Allergic Rhinitis. Power-Pak C.E. Jobson Publishing Group. Published September 2005: 1-12.
176. Zagaria MA. Vaginal Bleeding in Postmenopausal Women. US Pharm. 2005;30(9):22-26.
177. Zagaria MA. OTC Medication Use in Seniors. US Pharm. 2005;30(8):24-26.
178. Zagaria MA. Tips for Traveling Seniors. US Pharm. 2005;30(7):32-36.
179. Zagaria MA. Altered Sleep in Seniors. US Pharm. 2005;30(6):32-38.
180. Zagaria MA. The Effects of Aging on Drug Efficacy. US Pharm. 2005;30(5):54-57.
181. Zagaria MA. Medication Therapy Management Services. US Pharm. 2005;30(4):35-42.
182. Zagaria MA. Abnormal Blood Pressure Homeostasis. US Pharm. 2005;30(3):29-33
183. Zagaria MA. Geriatric Syndromes. US Pharm. 2005;30(2):29-34.
184. Zagaria MA. Implications of Dysphagia. US Pharm. 2005;30(1):30-39.
185. Cooper CB, Zagaria MA. New Advances in the Management of COPD. Accreditation Council for Pharmacy Education. Program Number: 809-999-05-001-H01. Released January 31, 2005.
186. Perfetto E, Barber A, Atkinson W, Zagaria MA. Monitoring and Evaluation: Demonstrating Improved Care Processes and Patient Outcomes. In: Developing a Senior Care Pharmacy Practice: Your Guide and Tools for Success. 2004. American Society of Consultant Pharmacists. 2004: 123-132
187. Zagaria MA, Feldman S. Introduction. In: Developing a Senior Care Pharmacy Practice: Your Guide and Tools for Success. 2004. American Society of Consultant Pharmacists. 2004: 5-11.
188. Zagaria MA. Herpes Zoster, or Shingles, is Painful: Increased Risk in Seniors. US Pharm. 2004;29(12):33-38.
189. Zagaria MA. Risk in Clinical Trials Versus Clinical Practice: Drug-Induced Hyperkalemia. US Pharm. 2004;11:29-34
190. Zagaria MA. Low Health Literacy: Raising Awareness for Optimal Health Communication. US Pharm. 2004;29(10):41-48
191. Zagaria MA. Carpal Tunnel Syndrome: A Major Entrapment Neuropathy in the Elderly. US Pharm. 2004;29(9):30-36
192. Zagaria MA. Prevention of Prostate Cancer: Study Investigates Vitamin E and Selenium. US Pharm. 2004;29(8):32-38.
193. Zagaria MA. Managing the Elderly with Stable COPD. US Pharm. 2004;29(7):32-38.
194. Zagaria MA. Pharmacoeconomics in Senior Care: Balancing Costs and Outcomes. US Pharm. 2004;29(6):32-37.
195. Zagaria MA. Insomnia, Depression, and Suicide Risk in the Elderly. US Pharm. 2004;29(5):30-37
196. Zagaria MA. Superficial Fungal Infections: Considerations in Treatment Plans. US Pharm. 2004;29(4):20-24.
197. Zagaria MA. Seniors as Caregivers US Pharm. 2005;29(3):16-25.
198. Zagaria MA. Recommended screenings for older adults. Modern Pharmacy June 2004;11(6):6-7.
199. Zagaria MA. Hearing loss in the elderly. Modern Pharmacy. June 2004;11(6):8-10.
200. Zagaria MA. Aspirin Resistance. US Pharm. 2004;29(2):41-46.
201. Zagaria MA. The Promise of Pharmacogenomics. US Pharm. 2004;29(1):31-36.
202. Zagaria MA. Sexually Transmitted Diseases in Older Adults. US Pharm.2003;28(12):26-29.
203. Zagaria MA. Hyperglycemia Due to Atypical Antipsychotics. US Pharm.2003;28(11):20-23.
204. Zagaria MA. Transient Ischemic Attacks. US Pharm.2003;28(10):28-31.
205. Zagaria MA. Dizziness and Vertigo in Seniors. US Pharmacist 2003;28(9):28-32.
206. Zagaria MA. Benign Prostatic Hyperplasia. US Pharm.2003;28(8):28-34.
207. Zagaria MA. Common Tremors in the Elderly. Modern Pharmacy 2003;10(8):22-24
208. Zagaria MA. Aspiration Pneumonia. US Pharm.2003;28(7):28-33.
209. Zagaria MA. Hemorrhoids: Treatment Options. US Pharm.2003;28(6):28-33.
210. Zagaria MA. Drug-Induced Acute Renal Failure: Nonsteroidal Anti-Inflammatory Drugs. US Pharmacist 2003;28(5):19-23.
211. Zagaria MA. Drug-Induced Acute Renal Failure: Angiotensin II Converting Enzyme Inhibitors and Receptor Blockers. US Pharm.2003;28(4):29-33.
212. Zagaria MA. Lumbar Spinal Stenosis. US Pharm.2003;28(3):28-30.
213. Zagaria MA. Hearing Loss in the Elderly. US Pharm.2003;28(2):13-15.
214. Zagaria MA. End-of-Life Care in the Elderly. US Pharm.2003;28(1):20-23.
215. Zagaria MA. Legal Aspects of Eldercare: The Living Will, Healthcare Proxy and Do-Not-Resuscitate (DNR) Order. US Pharm.2002;27(12):68-69.
216. Zagaria MA. Appropriate Monitoring Parameters for Epoetin Alfa Therapy for Anemia Associated with Chronic Renal Failure (CRF). US Pharmacist 2002;27(11):52-54.
217. Zagaria MA. Postherpetic Neuralgia. US Pharm. 2002;27(10):21-23.
218. Zagaria MA. Visual Consequences of the Aging Eye: Falls and Driving Accidents Among Seniors. US Pharm. 2002;27(8):33-36.
219. Zagaria MA. Senior Health Maintenance Part II: Cognitive and Nutritional Fitness. US Pharm. 2002;27(7):21-23.
220. Zagaria MA. Senior Health Maintenance Part I: Exercise. US Pharmacist. 2002;27(6):35-38.
221. Zagaria MA. Disinhibition as a Complication of Benzodiazepine Therapy. US Pharmacist. 2002;27(5):37-41.
222. Zagaria MA. Recommended Screenings for Older Adults. US Pharmacist. 2002;27(3):37-41.
223. Zagaria MA. Common Tremors in the Elderly: Symptom or Side Effect? US Pharmacist. 2002;27(1):23-28.
224. Zagaria MA. The Elderly Diabetic and Autonomic Neuropathy. US Pharmacist. 2001;26(11):28-31.
225. Zagaria MA. Urinary Incontinence: Care, Complications, and Cost. US Pharmacist. 2001;26(10):28-33.
226. Zagaria MA. Osteoporosis and Prediction of Fracture Risk. US Pharmacist. 2001;26(09):28-39.
227. Zagaria MA. Sciatica in Older Adults. US Pharmacist. 2001;26(08):41-46.
228. Zagaria MA. New Guidelines for Cholesterol Management. US Pharmacist. 2001;26(07):29-33.
229. Zagaria MA. Pharmacist Interventions Can Prevent Falls. US Pharmacist. 2001;26(05):79-81.
230. Zagaria MA. TIA, Stroke, and the Importance of Post-Stroke Rehabilitation. US Pharmacist. 2001;26(02):39-40.
231. Zagaria MA. Alzheimer’s Disease: Focus on Early Diagnosis and Treatment. US Pharmacist. 2001;26(01):36-40.
232. Zagaria MA. Gestational Diabetes Mellitus: Risks, Complications, and Therapeutic Outcomes. US Pharmacist. 2000;25(11):50-56.
233. Zagaria MA. Nutrition in the Elderly: Undernutrition Perpetuates the Process of Physical, Cognitive, and Functional Decline. US Pharmacist. 2000;25(10):42-44.
234. Zagaria MA. Temporal Arteritis: When Headache Can Lead to Blindness. US Pharmacist. 2000;25(9):78-79.
235. Zagaria MA. Actinic Keratosis: Sun Exposure and Cancer Risk. US Pharmacist. 2000;25(8):25-25.
236. Zagaria MA. Avoiding Adverse Effects in the Elderly. US Pharmacist. 2000;25(6):73
237. Zagaria MA. Insomnia in the Elderly. US Pharmacist. 2000;25(5):81
238. Zagaria MA. Depression: An Under treated Illness. US Pharmacist. 2000;25(4):111
239. Zagaria MA. Pain Management. US Pharmacist. 2000;25(3):70-73.
240. Zagaria ME. Pharmaceutical Care of the Older Patient. US Pharmacist. 2000;25(2):94-97
241. Zagaria MA1. Quality of life: issues for the pharmacist. Am Pharm. 1995 May;NS35(5):52-7. PMID: 7611140